✦ LIBER ✦

A Case of Severe Chronic Heart Failure Successfully Controlled with Long Term Administration of Tolvaptan; a V(2)-specific Vasopressin Receptor Antagonists

✍ Scribed by Yuna Yamagami; Hideyuki Kinoshita; Koichiro Kuwahara; Yoshihiro Kuwabara; Shinji Yasuno; Satoru Usami; Yasuaki Nakagawa; Toshio Nishikimi; Kenji Ueshima; Kazuwa Nakao

Book ID: 116341287
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 80 KB
Volume: 17
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2011.06.565

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of the Vasopressin V2 Receptor A

Effects of the Vasopressin V2 Receptor Antagonist, Tolvaptan, on the Long-term Progression of Left Ventricular Dilatation in Patients with Heart Failure

✍ James E. Udelson 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Effects of Lixivaptan, a Novel Vasopress

Effects of Lixivaptan, a Novel Vasopressin V2 Receptor Antagonist, in Chronic Heart Failure: Results from a Double-Blind, Placebo-Controlled, Multiple-Dose Study

✍ William Abraham; Steven Goldsmith; Stephen Gottlieb 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Acute Hemodynamic Effects of Tolvaptan,

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction: An International, Multicenter, Randomized, Placebo-Controlled Trial

✍ James E. Udelson; Cesare Orlandi; John Ouyang; Holly Krasa; Christopher A. Zimme 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 561 KB

Acute Hemodynamic Effects of Tolvaptan,

Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial

✍ James E. Udelson; Cesare Orlandi; John Ouyang; Holly Krasa; Christopher A. Zimme 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 96 KB